Hologic, Inc. (HOLX) FCF Payout Ratio: N/A
The FCF payout ratio for Hologic, Inc. (HOLX) is N/A.
HOLX FCF Payout Ratio Metrics
FCF PAYOUT RATIO
N/A
Payout Ratio Comparison
FCF Payout Ratio
N/A
Earnings Payout Ratio
N/A
Dividend Yield
N/A
FCF Yield
5.82%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $920.10M | $0 | 0.0% |
| 2024 | $1.15B | $0 | 0.0% |
| 2023 | $901.00M | $0 | 0.0% |
| 2022 | $2.00B | $0 | 0.0% |
| 2021 | $2.15B | $0 | 0.0% |
| 2020 | $740.20M | $0 | 0.0% |
| 2019 | $535.90M | $0 | 0.0% |
| 2018 | $627.30M | $0 | 0.0% |
| 2017 | ($99.30M) | $0 | N/A (Loss) |
| 2016 | $688.70M | $0 | 0.0% |
| 2015 | $696.70M | $0 | 0.0% |
| 2014 | $428.20M | $0 | 0.0% |
| 2013 | $403.69M | $0 | 0.0% |
| 2012 | $286.95M | $0 | 0.0% |
| 2011 | $392.02M | $0 | 0.0% |
| 2010 | $404.23M | $0 | 0.0% |
| 2009 | $480.66M | $0 | 0.0% |
| 2008 | $311.31M | $0 | 0.0% |
| 2007 | $130.41M | $0 | 0.0% |
| 2006 | ($9.46M) | $0 | N/A (Loss) |
| 2005 | $36.67M | $0 | 0.0% |
| 2004 | $18.70M | $0 | 0.0% |
| 2003 | ($3.42M) | $0 | N/A (Loss) |
| 2002 | $823,000 | $0 | 0.0% |
| 2001 | ($14.58M) | $0 | N/A (Loss) |
| 2000 | ($6.50M) | $0 | N/A (Loss) |
| 1999 | ($6.60M) | $0 | N/A (Loss) |
| 1998 | ($8.00M) | $0 | N/A (Loss) |
| 1997 | $10.50M | $0 | 0.0% |
| 1996 | ($1.30M) | $0 | N/A (Loss) |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Hologic, Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini